Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5778817 | 0.88 | MEN1 (0.56) | MEN1KMT2AALDH1A1MAPTCHRM2 | |
| SCHEMBL7534318 | 0.86 | MEN1 (0.47) | MEN1KMT2AALDH1A1MAPTHSD17B10 | |
| SCHEMBL9387391 | 0.84 | CYP2D6 (0.47) | MEN1KMT2ANAMPTALDH1A1CYP2D6 | |
| SCHEMBL2394181 | 0.81 | NAMPT (0.58) | MEN1KMT2ANAMPTALDH1A1MAPT | |
| SCHEMBL9074062 | 0.80 | KDM4E (0.54) | KMT2ANAMPTALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6640189 | 0.78 | LMNA (0.54) | MEN1KMT2AALDH1A1MAPTCHRM2 | |
| SCHEMBL28896002 | 0.77 | ALDH1A1 (0.49) | MEN1KMT2ANAMPTALDH1A1MAPT | |
| SCHEMBL9180541 | 0.76 | GRM5 (0.53) | MEN1KMT2AALDH1A1MAPTHSD17B10 | |
| SCHEMBL23044593 | 0.75 | MEN1 (0.57) | MEN1KMT2AALDH1A1MAPTHSD17B10 | |
| SCHEMBL4772546 | 0.75 | NAMPT (0.49) | MEN1KMT2ANAMPTALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391690-B2 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | LIGACHEM BIOSCIENCES INC. (KR) | 2025-08-19 | — | — | US | disclosed |
| CN-116803980-A | Preparation method of tetrahydropyridine derivative and hexahydropyridine derivative | 中国科学院化学研究所 | 2023-09-26 | — | — | CN | disclosed |
| US-20230123569-A1 | COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LIGACHEM BIOSCIENCES INC. (KR) | 2023-04-20 | — | — | US | disclosed |
| US-20230123569-A1 | COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LIGACHEM BIOSCIENCES INC. (KR) | 2023-04-20 | — | — | US | disclosed |
| US-11548883-B2 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | LEGOCHEM BIOSCIENCES, INC. (KR) | 2023-01-10 | — | — | US | disclosed |
| US-11548883-B2 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | LEGOCHEM BIOSCIENCES, INC. (KR) | 2023-01-10 | — | — | US | disclosed |
| EP-3442973-B1 | NOVEL COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LEGOCHEM BIOSCIENCES INC (KR) | 2022-08-31 | — | — | EP | disclosed |
| CN-109476664-B | Novel compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | 乐高化学生物科学股份有限公司 | 2021-08-10 | — | — | CN | disclosed |
| US-10961242-B2 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | LEGOCHEM BIOSCIENCES, INC. (KR) | 2021-03-30 | — | — | US | disclosed |
| US-10961242-B2 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | LEGOCHEM BIOSCIENCES, INC. (KR) | 2021-03-30 | — | — | US | disclosed |
| US-8580807-B2 | Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120021976-A1 | BICYCLIC PIPERIDINE AND PIPERAZINE DERIVATIVES AS GPCR MODULATORS FOR THE TREATMENT OF OBESITY, DIABETES AND OTHER METABOLIC DISORDERS | MERCK SHARP & DOHME LLC | 2012-01-26 | — | — | US | disclosed |
| US-20120021976-A1 | BICYCLIC PIPERIDINE AND PIPERAZINE DERIVATIVES AS GPCR MODULATORS FOR THE TREATMENT OF OBESITY, DIABETES AND OTHER METABOLIC DISORDERS | MERCK SHARP & DOHME LLC | 2012-01-26 | — | — | US | disclosed |
| WO-2010114957-A1 | BICYCLIC PIPERIDINE AND PIPERAZINE DERIVATIVES AS GPCR MODULATORS FOR THE TREATMENT OF OBESITY, DIABETES AND OTHER METABOLIC DISORDERS | SCHERING CORPORATION (US) | 2010-10-07 | — | — | WO | disclosed |
| US-7795436-B2 | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-14 | — | — | US | disclosed |
| US-20070049613-A1 | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-20040092737-A1 | Benzopiperidine derivatives | EISAI CO., LTD. | 2004-05-13 | — | — | US | disclosed |
| US-6518423-B1 | These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and | EISAI CO., LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| US-6166037-A | Pyrrolidine and piperidine modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2000-12-26 | — | — | US | disclosed |
| EP-0934941-A1 | BENZOPIPERIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | HLA-DRB1, HRH1, HRH2 | MEN1 4580/4885KMT2A 3395/4885NAMPT 3813/4885 |
| US-11548883-B2 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | ENPP2, PLA2G10, LPCAT1 | MEN1 1247/4885KMT2A 1905/4885NAMPT 1921/4885 |
| US-20230123569-A1 | COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | ENPP2, PLA2G10, LPCAT1 | MEN1 1247/4885KMT2A 1905/4885NAMPT 1921/4885 |
| US-12391690-B2 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | ENPP2, PLA2G10, LPCAT1 | MEN1 1247/4885KMT2A 1905/4885NAMPT 1921/4885 |
| US-20120021976-A1 | BICYCLIC PIPERIDINE AND PIPERAZINE DERIVATIVES AS GPCR MODULATORS FOR THE TREATMENT OF OBESITY, DIABETES AND OTHER METABOLIC DISORDERS | GPR119, GPR55, GPR4 | MEN1 4566/4885KMT2A 1713/4885NAMPT 1590/4885 |
| US-10961242-B2 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | ENPP2, PLA2G10, LPCAT1 | MEN1 1247/4885KMT2A 1905/4885NAMPT 1921/4885 |
| US-20070049613-A1 | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists | HTR2B, HTR2C, HTR1A | MEN1 2162/4885KMT2A 3546/4885NAMPT 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.